SCHEMBL4924312

SCHEMBL4924312

Cc1ccccc1Nc1ncnc2c1cnn2-c1cccc(N2CCC(N3CCN(C)CC3)CC2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.60
SMN1; SMN2 Q16637 5/20 0.60
NPC1 O15118 4/20 0.60
RAB9A P51151 4/20 0.60
HSD17B10 Q99714 3/20 0.60
HTT P42858 3/20 0.60
TSHR P16473 2/20 0.60
TP53 P04637 7/20 0.56
MAPT P10636 6/20 0.53
KDM4E B2RXH2 3/20 0.50
HPGD P15428 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPK14 Q16539 3/20 0.48
ALDH1A1 P00352 3/20 0.47
MAPK1 P28482 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4920822 0.92 TP53 (0.64) LMNASMN1; SMN2NPC1RAB9AHSD17B10
SCHEMBL4925776 0.91 LMNA (0.69) LMNASMN1; SMN2NPC1RAB9AHSD17B10
SCHEMBL4929583 0.91 MAPT (0.51) LMNASMN1; SMN2NPC1RAB9AHSD17B10
SCHEMBL4925084 0.89 TP53 (0.64) LMNASMN1; SMN2NPC1RAB9AHSD17B10
SCHEMBL4929204 0.85 TP53 (0.52) LMNASMN1; SMN2NPC1RAB9AHSD17B10
SCHEMBL4925264 0.85 TP53 (0.66) LMNASMN1; SMN2NPC1RAB9AHSD17B10
SCHEMBL4921984 0.83 LMNA (0.64) LMNASMN1; SMN2NPC1RAB9AHSD17B10
SCHEMBL4926382 0.83 LMNA (0.61) LMNASMN1; SMN2NPC1RAB9AHSD17B10
SCHEMBL4926073 0.83 LMNA (0.54) LMNASMN1; SMN2NPC1RAB9AHSD17B10
SCHEMBL4925406 0.82 LMNA (0.64) LMNASMN1; SMN2NPC1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors NOVARTIS AG (CH) 2008-04-24 US claimed
CN-101098873-A 1, 4-substituted pyrazolopyrimidines as kinase inhibitors NOVARTIS AG (CH) 2008-01-02 CN claimed
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors NOVARTIS AG (CH) 2008-04-24 US disclosed
CN-101098873-A 1, 4-substituted pyrazolopyrimidines as kinase inhibitors NOVARTIS AG (CH) 2008-01-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors MAP3K1, MAP4K2, MAP4K5 LMNA 3959/4885SMN1; SMN2 1610/4885NPC1 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.